move along acut migrain data file
adam partner materi catalyst
zosano continu advanc novel robust acut migrain
therapeut long-term safeti studi safeti data
patient use slot solid commerci
manufactur strategi fund place posit safeti
serv addit de-risk event zsan share
continu believ substanti role difficult-to-treat
well-establish migrain nausea materi
estim us approv peak sale
long-term safeti studi track zosano disclos seriou drug-
relat number type sever report within
expect efficaci remain consist migrain
treat hour patient pain freedom
bothersom symptom freedom pain relief
partner effort heat zosano expect begin
partner discuss earnest regard broader applic
adam technolog expect talk focu three potenti
opportun acut migrain emerg pipelin program
one two could disclos use adam technolog
rais awar zosano activ rais awar
differenti profil public present
medic meet expect effort continu
op ep slightli estim
spend slightli estim act vs estimate
impress efficaci show pain freedom hour
vs placebo freedom next
bothersom symptom vs placebo
pain relief hour measur describ one correl much
better restor function robust vs
placebo hour compar inject triptan
zsan appear attract zsan estim stand-alon npv
 potenti lift zsan target
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
exhibit effect hard treat migrain popul
tepper et al efficaci intracutan zolmitriptan acut treatment difficult treat
focus
fremont california-bas
develop
commerci medicin use novel deliveri technolog lead
asset near complet clinic evalu acut treatment
migrain headach form part spin-off alza corporation/
johnson johnson review zosano mission fulli
advanc adam adhes dermally-appli microarray microproject
deliveri technolog success advanc zp-triptan
pivot efficaci develop notabl zosano work fda
develop effici regulatori strategi util
regulatori pathway posit readout hand
requir efficaci studi zosano briskli enrol long-term safeti studi
support nda file acut migrain addit zosano
early-stag effort underway employ adam technolog
platform broadli believ potenti partnership
addit adam program time
exhibit zosano novel adam zolmitriptan acut
treatment migrain headach
kellerman et al pharmacokinet toler new intracutan microneedl system
pain relief
hour
inject
end-
point
good
measur
restor
function
acut migrain injectable-lik efficaci without inject
zosano primari asset novel formul one potent
triptan zolmitriptan deliveri zolmitriptan uniqu compar
standard oral inject nasal approach result believ
potenti offer differenti commerci profil provid
intraderm deliveri zolmitriptan microproject align
array small adhes patch size quarter exhibit
use system zosano complet posit zotrip pivot studi
acut treatment migrain headach convinc efficaci
result compani current enrol long-term safeti studi
acut migrain complet clinic work nda
characterist appear promis rapid
robust durabl efficaci pain relief compar inject triptan
without challeng inject inject site pain phobia
exhibit achiev compar pain relief inject sumatriptan
posit top-line result zotrip pivot efficaci studi
acut treatment migrain zotrip trial pain
freedom rate co-primari endpoint versu placebo
dose exhibit left co-primari
endpoint freedom bothersom addit associ symptom
migrain hour subject achiev freedom
compar placebo exhibit right importantli
rapid onset pain freedom seen nomin
underscor activ collect find result convinc
regard rapid robust efficaci profil
freedom left bothersom symptom freedom right
materi potenti acut migrain zosano complet
enrol long-term safeti studi finish
nda file potenti approv
safeti profil patient use drug least twice per month
month match prior clinic work rapid robust efficaci compar
inject triptan believ abil consid one
efficaci therapi acut migrain importantli pivot
zotrip studi also perform well difficult-to-treat migrain
migrain attack occur earli morn alreadi
fulli develop upon wake patient achiev materi
pain freedom rate vs placebo nomin p-valu quit
compar overal popul data along sustain
efficaci hour dose reinforc notion
provid highli efficaci non-or needle-fre option migrain
patient may difficulti unsatisfi oral therapi due
lack efficaci nausea/gastroparesi repres
migraineur solid efficaci result hand larg billion triptan
migrain market us non-or alreadi repres grow
million acut migrain believ achiev regulatori approv
zosano lever intrigu profil peak revenu exceed million
promis profil acut migrain
 injectable-lik efficaci acut migrain
 robust sustain efficaci hour
 highli activ established/morn migrain
 highli activ materi nausea/gastroparesi
suggest
option
limit
rout
al cephalalgia
zosano zsan share valuat zosano oper
potenti signific revenu earn variabl come
quarter year valu compani asset use fully-tax risk-
weight net present valu methodolog asset note
advanc signific clinic program compris lion
share zosano asset valuat given estim potenti clinic
regulatori commerci success current estim modest
increment valu futur develop zosano adam technolog
platform beyond activ biotechnolog sector regular
occurr possess posit pivot efficaci believ
potenti exist zosano therefor valu zsan share probabl
weight two scenario zosano oper independ zosano
acquir larger biopharmaceut player
scenario zosano oper independ assess total valu
per zsan share assum zosano continu oper
independ collect assess total valu program
asset per zsan share exhibit
assess zosano asset zosano advanc asset appear
offer uniqu commerci profil compar triptan formul
acut migrain novel deliveri mechan provid
rapid robust efficaci compar oral nasal triptan
materi consider patient fulli develop migrain morn
migrain other yet less invas fussi compar
inject nasal form triptan give revenu potenti exceed
million us acut migrain despit presenc gener
convinc phase efficaci data publish well-character
clinic profil zolmitriptan long-term safeti data upcom util
discount rate per year revenu earn stream
given posit view potenti licensur sinc migrain
indic potenti opportun rel effici market
revenu potenti creat risk-weight npv exhibit
nol credit add corpor drag
cost per zsan share consider npv calcul
includ million zsan share outstand effect tax rate
scenario zosano take-over chang basic assumpt
take-over scenario includ global econom zosano pipelin flow
potenti suitor also assum less increas sg expens sinc
scale effici would like gain larger establish
suitor addit chang includ corpor effici gain take-over
corpor drag reduc inclus chang control premium
off-set bit use fulli dilut share collect take-over
valuat result npv per fulli dilut zsan share exhibit
probabl weight scenario lead price
probabl weight scenario assign probabl zosano oper
independ take-over anoth entiti lead overal
npv price target per zsan share
oct fda issu new draft guidanc develop drug
acut migrain octob fda publish draft guidanc migrain
develop drug acut treatment propos altern approach
measur efficaci novel agent clinic develop acut migrain
use co-primari endpoint freedom headach pain hour
post-dos freedom next bothersom migraine-
associ symptom headach pain hour post-dos new
endpoint simplifi clarifi studi design develop
therapeut treatment condit
zosano focus zosano restructur oper focu
develop zp-triptan follow posit phase data fda
feedback regulatori pathway program specif agreement
singl posit pivot efficaci studi long-term safeti studi could
support approv approv pathway zosano
reduc headcount employe paus develop
candid zp-pth zp-glucagon asset particularli zp-pth
may revisit busi develop effort
zosano asset pipelin adam credit control premium
zosano rais million zosano rais net proce million
pipe offer share per share
warrant cost per warrant zosano manag board member
particip privat round
feb posit top line pivot data februari
zosano announc highli posit top line result zotrip
acut treatment migrain dose met co-primari
endpoint pain freedom rate vs placebo
also led freedom bothersom migraine-
associ symptom hour vs placebo
treatment benefit placebo pain
bothersom symptom notabl differenti benefit observ
oral small molecul approach exhibit view
zosano rais million zosano rais net proce
million offer million zsan share per share
june end phase fda meet confirm regulatori
strategi zosano end phase meet fda among element
confirm posit zotrip trial suffici support nda
file approv also design long-term safeti studi
suffici support nda file separ fda commun zosano
propos chemic manufactur control develop
strategi also appear adequ registr
june zotrip efficaci data present american
headach societi meet dr egiliu spier investig zotrip
clinic professor neurolog craniofaci pain tuft univers
school medicin dental medicin present pivot zotrip
dataset first time includ secondari endpoint late-
break session american headach societi meet
dateeventcom updat acut migrain develop draft guidanceguid reflect zotrip trial restructur focus posit data approv pivot zotrip trial beginsposit data provid basi posit zotrip top-line dose injection-lik efficaci rais millionfund continu phase meet fda zotrip data enough fo us nda design data present american headach meetingprimari secondari data late-break session pk profil publish pain rapid drug data intern headach conferencekol discuss use morn migrain mb zotrip pivot data publish cephalalgiaposit robust efficaci data potenti us long-term safeti studi launchesfin piec clinic data file final acut migrain develop guidancereflect posit zotrip studi patent issu patent exclus rais million net fund safeti studi pre-commerci long-term safeti studi fulli enrolledenrol ahead schedul data support nda bothersom symptom endpointheadach public support use mb co-primari vitro skin model publish pharmaceuticsdermatom skin vitro model aid adam developmentvvv signific least import vvvvv import
juli differenti pk profil publish pain manag
differenti rapid pk profil assess healthi volunt
data publish kellerman et al pain manag single-
center open-label phase effort show dose drug
absorpt rapid median tmax achiev within minut
compar tmax subcutan sumatriptan accord
kellerman et al tmax minut oral zolmitriptan dose
cmax maximum drug concentr exposur
hour materi higher oral zolmitriptan
sept zotrip pivot data present
includ oral
present dr david kudrow assist clinic professor neurolog
ucla david geffen school medicin describ broad zotrip data
two addit late-break poster one dr david dodick professor
neurolog mayo clinic describ use bothersom
symptom endpoint zotrip studi dr pete schmidt
zosano present post hoc analysi patient zotrip studi
morn migrain support data present well-regard kol
field migrain headach suggest interest
oct posit zotrip data publish cephalalgia posit data
random double-blind placebo-control us pivot zotrip studi
publish spier et al analysi includ patient
histori migrain per month random
placebo previous discuss met co-
primari endpoint pain freedom vs
bothersom migraine-associ symptom hour vs
superior pain freedom
signific bothersom symptom improv pain freedom
earli minut vs nomin underscor
molecul rapid onset addit post hoc analys patient
treat sustain pain freedom first hour
compar favor rate seen control clinic trial
triptan accord author advers event also appear dose-
depend three sever treatment-emerg arm
two patient discontinu dose
long-term safeti studi launch zosano enrol first
patient onto open-label long-term safeti studi last clinic
hurdl file nda treatment acut migrain trial
assess safeti profil
patient use treat migrain per month
endpoint includ ecg lab rate pain-fre respons
feb fda final guidanc industri migrain fda final
draft guidanc industri migrain develop drug acut
treatment nomin fda prefer approach evalu efficaci
co-primari endpoint headach pain hour post-dos
demonstr effect bothersom migraine-associ symptom
hour post-dos secondari endpoint measur effect
import migrain symptom nausea photophobia phonophobia
independ addit pain-fre timepoint use rescu medic
sustain pain-fre outcom pain relaps
march zosano extend patent protect least
uspto issu key patent extend patent protect
least patent method rapidli achiev therapeut
concentr triptan treatment migrain cover
formul method use deliveri manufactur among other
net sale million share proce fund
long-term safeti studi oper plan nda file
may long-term safeti studi fulli enrol ahead
schedul may zosano report fulli enrol safeti
studi ahead expect timelin addit patient
run-in period allow enrol elig also zosano
disclos migrain treat sinc studi
launch seriou observ notabl pain freedom
pain relief hour studi accord zosano
may public bothersom symptom endpoint
zotrip trial dr david dodick mayo clinic other
publish post-hoc analysi zotrip trial headach extrapol
result legaci migrain co-primari endpoint pain relief nausea
photophobia phonophobia author conclud co-primari
endpoint freedom bothersom symptom feasibl
desir altern use co-primari endpoint acut migrain
treatment trial believ public also help physician
evalu robust efficaci compar exist emerg acut
june public vitro skin model
preclin data publish journal pharmaceut identifi human
dermatom skin lower region dermi capillari
bed remov best estim vivo activ drug-cov
adam microproject use franz human skin finit dose model
human full thick skin synthet skin result poor absorpt
could result underestim adam drug releas vivo result
suggest dermatom vitro skin model may suffici estim drug
vivo profil aid continu develop adam technolog
dateeventcom importancejun american headach societi oral poster present reinforc solid publications/present possiblepub drive increas awar commerci manufactur readi progressregistr batch month result long-term safeti studi announcedskin toler focu lt safeti develop adam deliveri platformadam deliveri platform technolog could lead month long-term safeti dataposit skin toler support nda nda file accept acut migrainecould lead potenti us approv launch fda approv acut migrainepotenti us approv launch least import vvvvv import
june american headach societi meet addit
data present oral present bind kinet
zolmitriptan n-desmethyl-zolmitriptan sumatriptan two poster
present rapid system absorpt zolmitriptan
associ high rate pain relief incid moder
sever pain recurr analysi ligand-receptor kinet
zolmitriptan primari metabolit sumatriptan note
believ present highli support profil
commerci manufactur readi zosano began scale
manufactur infrastructur back half product
registr batch requir nda file began earli
final batch place stabil
continu awar public zosano
continu gener awar robust clinic data packag
zotrip studi addit public
safeti data data patient long-term
open label safeti studi treat least migrain per month
expect around yearend
potenti new partnership zosano
attempt leverag broad potenti adam intracutan deliveri
technolog previous gener data earlier program zp-pth
partnership zosano effort target indic rapid drug
deliveri could provid patient therapeut benefit within
safeti data final clinic hurdl nda
data includ patient use treat migrain
per month period last clinic mileston requir
support file nda treatment acut migrain zosano
expect data around end note zosano upon receipt
minut end phase meet fda agenc primari
emphasi confirm skin toler month
nda file acut migrain long-term safeti
studi read assum posit compani expect posit
file nda fda treatment acut migrain approv
launch expect
 potenti possibl sinc zosano effect one product
compani modest infrastructur reason chanc
larger industri suitor could emerg take compani oper
time event alway challeng though awar
build robust pivot efficaci data differenti deliveri profil
compar highli efficaci migrain therapeut progress
long-term safeti studi believ real possibl
time least closer nda approv view
zosano pharma summari zosano focus develop
commerci medicin use novel adam adhes dermally-
appli microarray microproject deliveri technolog zosano form
spin-off alza/johnson johnson fulli advanc adam
technolog zosano success advanc pivot
efficaci studi acut migrain util regulatori pathway
highli posit readout singl requir efficaci studi hand
zosano briskli enrol long-term safeti studi support nda
file acut migrain addit zosano early-stag
effort underway employ adam platform broadli believ
potenti partnership addit adam program time
meantim believ bulk investor interest zosano zsan
share program acut treatment migrain
exhibit symptomat cascad migrain
chronic
neurovascular disord character sever recurr headach
approxim adult popul experienc migrain one
common preval disabl neurolog condit
migraineur gener lower threshold trigger might caus
neuron hyperexcit includ sleep disturb environment
emot challeng alcohol exposur diet hormon cycles/chang
among other migrain attack usual last hour migrain
headach typic throb unilater one side aggrav
physic activ migrain typic present addit symptom
addit headach pain includ nausea sensit light and/or
sound exhibit diagnosi migrain intern headach societi
ih criteria requir combin characterist
associ symptom least five attack two major subtyp
migrain migrain without aura common migrain migrain aura
migrain caus earli theori caus migrain larg
influenc work wolff propos
extracrani dilat pivot
caus migrain headach
hypothesi eventu reinforc knowledg ergot alkaloid
select receptor agonist triptan develop
rel select cranial vasoconstrictor effect treatment
migrain recent evid posit migrain occurr independ
chang blood vessel moskowitz cephalalgia instead
primarili neuron diseas unknown pain trigger thought stimul
trigemin ganglia innerv cephal tissu vasculatur result
releas vasoact neuropeptid cgrp potent vasodil
neuropeptid believ multipl sequela one pain
modul therefor becom focu therapeut develop
migrain preval diseas burden migrain headach affect
popul us women men million
individu us accord american migrain foundat
make lead caus disabl among neurolog disord
direct indirect cost migrain us estim billion
annual condit common work popul
year age common disabl disord need
effect rapid treatment import
migrain current treatment approach approach pharmacolog
treatment migrain includ therapeut acut treat migrain attack
aris acut treatment migrain therapeut reduc
frequenc migrain attack prevent treatment acut treatment
includ common over-the-count over-the-counter pain reliev combin
moder effect initi therapeut acut treatment mild
moder migrain often affect over-the-counter drug aspirin
acetaminophen nsaid ibuprofen naproxen combin
agent also consid howev headach increas
frequenc increas sever potent therapeut introduc
prescript therapeut acut treatment migrain inject
nasal ergot alkaloid util challeng migrain case though
widely-us class acut migrain therapeut triptansimitrex
sumatriptan zomig zolmitriptan maxalt rizatriptan other potent
oral therapi develop base abil constrict intracrani
blood vessel agonist activ receptor howev
sinc receptor also wide present non-crani vasculatur triptan
carri risk caus coronari vasoconstrict therefor formal
contraind patient cardiovascular cerebrovascular diseas
product label recommend migrain patient cardiovascular
diseas risk factor evalu silent myocardi ischemia receiv
triptan dose initi triptan dose administ medic
supervis set also triptan produc rel high incid
neck jaw chest symptom high limit toler
patient complianc emerg therapeut class therapeut
agonist lasmiditan cgrp antagonist may play role
patient cardiovascular risk could materi expand market
result though approach acut migrain appear possess
top-level efficaci result seen inject triptan
imshealth pharmetr january-decemb cohort project us insur patient popul
famili tryptamine-bas drug develop account
approxim anti-migrain therapi prescrib offic visit
accord imshealth project data exhibit class drug
develop oral nasal subcutan transderm patch
formul though latter longer market also base data
oral formul sumatriptan formerli brand imitrex captur
half total first-lin patient share newli diagnos patient
rizatriptan maxalt eletriptan relpax second third
commonli use product gener version sumatriptan avail
sinc other also due becom gener next
year total us triptan sale acut migrain estim
billion annual sale
imshealth pharmetr january-decemb cohort project us insur patient
nsaid acetaminophen antiemet dhe
dihydroergotamin potent vasoconstrictor use sever
decad though littl prescrib opioid also consid
acut migrain carri materi abus liabil risk rapidli fall
favor prescrib non-or option acut migrain treatment alreadi
repres grow million acut migrain us
oral triptan complet answer despit widespread use
need effect acut treatment migrain headach
partial satisfi triptan typic migrain attack
respons oral triptan within two hour though symptom recur
within hour mean patient fail respond
even greater amount dissatisfi treatment migrain patient
also fail respond consist oral triptan part owe issu
nausea gastric stasi slow absorpt
unmet need remain acut migrain mani migrain patient
respond consist oral triptan standard care acut
migrain exist sever domain dissatisfact includ inadequ
relief slow onset relief recurr pain inabl achiev
materi function quickli take therapi though data
rel lack innov acut migrain therapeut
develop believ remain valid would will tri anoth
acut medicin treat migrain exhibit
exhibit attribut acut migrain seen import
potenti import player acut migrain
summari profil zp-triptan develop demonstr
rapid injection-lik efficaci acut treatment migrain without
baggag needl use simpl low-cost adam applic devic
patch product base zolmitriptan highli potent well-character
member triptan class fda approv zomig acut
treatment migrain oral nasal deliveri triptan zolmitriptan
act bind agonist activ receptor
intracutan deliveri system effici deliv
formul
zolmitriptan success complet pivot efficaci zotrip
acut migrain long-term safeti studi progress well enrol
ahead schedul zosano manag announc mid-may
profil continu expect rapid sustain efficaci in-lin
inject differenti deliveri mechan avoid needl
materi local toxic abil address suffer fulli
develop migrain morn migrain oral triptan non-
respond moder respond due nausea/gastr stasi estim
fda approv
exhibit adam system intracutan zolmitriptan deliveri
adam
 spier et al effect safeti new zolmitriptan absorpt microneedl array
acut treatment migrain zotrip studi meet
appli microarray adam zosano novel devic intracutan drug
deliveri exhibit adam technolog develop alza
corpor spun late form zosano devic includ two
part dispos array drug-coat titanium microproject
long diamet secur adhes back
appli low cost reusabl handheld applic microproject
shallow penetr stratum corneum outermost
layer skin limit local pain depth drug deliv proxim
adam deliveri easi use special dispos consider
drug coat microject patch packag foil cup store
room temperatur practic microarray patch appli use
applic releas patch suffici mild forc use
ensur equal applic patch worn minut dispos
without special handl sharp requir associ needl
schmidt et al experi delay treatment migrain use intracutan zolmitriptan
differenti rapid pk profil assess demonstr healthi
volunt data publish kellerman et al pain
drug crossov design assess pk zolmitriptan
tablet subcutan sumatriptan fast state dose
drug absorpt rapid median tmax achiev within minut
exhibit compar tmax subcutan
sumatriptan accord kellerman et al tmax minut oral
zolmitriptan dose cmax maximum drug concentr
exposur hour
materi higher oral zolmitriptan
addit less convers exposur n-desmethyl
zolmitriptan metabolit presum author due reduc first-
pass metabol portion drug lost absorpt gener liver
elh spier random double-blind placebo-control parallel-group multi-cent studi safeti efficaci
adam zolmitriptan acut treatment migrain cephalagia
data hit pivot zotrip trial co-primari endpoint
posit data random double-blind parallel group us
phase zotrip studi publish cephalalgia spier et al
analysi includ patient histori migrain per month
random placebo
met co-primari endpoint pain freedom vs
benefit freedom bothersom
migraine-associ symptom hour vs benefit
superior pain freedom show
signific bothersom symptom zotrip studi
fix sequenti test methodolog result
subsequ statist analys becom descript natur nomin
valu improv pain freedom earli minut vs
nomin underscor molecul rapid onset activ
efficaci appear dose-depend
exhibit achiev injection-lik pain relief hour
dodick et al use bothersom symptom co-primari endpoint migrain clinic trial
post-hoc analysi pivot zotrip random control trial headach
pain relief
hour
elh spier random double-blind placebo-control parallel-group multi-cent studi
safeti efficaci adam zolmitriptan acut treatment migrain cephalalgia
data achiev triptan injectable-lik perform pain
relief post-hoc analysi publish dr david dodick et al
headach may achiev pain relief hour
compar placebo nomin exhibit pain relief data
import sever reason view first quit robust larg
in-lin rate pain relief two clinic trial includ fda
product label imitrex inject vs placebo
strong perform pain relief measur also import
note recent discuss dr richard lipton well-recogn migrain
headach research hour pain relief measur one correl
much better restor function migrain patient
pain freedom endpoint better regulatory/fda endpoint
excel perform endpoint help patient
physician appreci strength result materi separ
placebo measur seen hour robust separ placebo
maintain hour exhibit help posit
mind patient physician spier et al cephalalgia comment
data suggest adam zolmitriptan may provid promis new
option provid rapid migrain relief circumv
limit rout administr
exhibit show durabl pain freedom hour
elh spier random double-blind placebo-control parallel-group multi-cent studi
safeti efficaci adam zolmitriptan acut treatment migrain cephalalgia
data pain freedom respons rapid durabl sustain
freedom pain consid ideal migrain treatment respons
spier et al post hoc analys patient treat
sustain pain freedom hour vs placebo nomin
compar favor rate seen control clinic
trial triptan accord spier et al even sustain pain
freedom hour achiev patient treat
compar placebo nomin
secondari endpoint also appear meaning note
cephalalgia public across dose group greater
proport patient free photophobia phonophobia nausea
hour dose irrespect pre-specified bothersom symptom
achiev photophobia freedom vs
placebo nomin percent achiev phonophobia freedom
vs nomin nausea achiev
nausea freedom vs placebo nomin
signific differ rate rescu medicin use across
entir studi though rate low placebo
exhibit percentag patient pain freedom
mb freedom pre-specified mb
dodick et al use bothersom symptom co-primari endpoint migrain clinic trial
post-hoc analysi pivot zotrip random control trial headach
safeti appear manag treatment emerg mild
moder sever patient appli full
minut vs placebo dose-respons effect observ
treatment-emerg three sever occur
arm includ local bruis local pain muscl tight
patient dose discontinu due importantli
seriou special interest
applic site reaction requir evalu care
result burn scar pigment reaction skin
resolv within day three event took day resolv
includ red placebo patient two patient
bruis major event prolong time resolut occur
patient take medic inhibit platelet function nsaid
fish oil consist safeti profil commonli seen clinic
trial triptan accord spier et al
exhibit common arm report pivot zotrip trial
elh spier random double-blind placebo-control parallel-group multi-cent studi safeti efficaci
adam zolmitriptan acut treatment migrain cephalagia
safeti appear favor imitrex inject label fda
product label imitrex sumatriptan inject includ safeti pool
placebo control studi rate dizziness/vertigo vs
placebo paresthesia tingl vs placebo though
head-to-head compar well zotrip dizzi
paresthesia studi overal atyp sensat inject site reaction
report patient treat imitrex respect
compar control
long-term safeti studi final clinic piec nda zosano
fulli enrol long-term safeti studi expect
final piec clinic data need support nda file studi
enrol patient histori migrain per
month enrol complet ahead schedul us site studi
evalu safeti profil patient use
patient use treat two migrain per
month endpoint includ ecg lab rate pain-fre respons
august updat encourag zosano disclos enrol patient
treat migrain estim nearli averag
studi pain freedom achiev pain relief hour
achiev migrain safeti drug-rel seriou advers
event observ date
fda interest lie skin toler note zosano upon
receipt minut end phase meet fda
agenc primari emphasi confirm skin toler
month greater monthli dose data expect around
end posit expect final clinic piec need
file nda acut treatment migrain believ
agenc concern long-term skin toler may driven rel
recent commerci experi zecuiti batteri power transderm
deliveri system sumatriptan worn hour devic led case
burn scar long-term skin reaction persist unresolv
month fda issu suspens market letter within month
launch product sinc discontinu
migrain market size accord decis resourc industri player
prescript drug sale triptan therapeut migrain estim
approxim billion zosano estim although current
market highli generic reformul triptan could
serv nich market patient hard treat migrain
respond deliveri mechan new therapeut class novel
mechan action expect contribut materi overal market
growth begin despit sever unsuccess attempt
notabl lack progress regard innov migrain market
rapid robust efficaci offer expect gener materi
interest certain popul difficulti use exist therapi
despit widespread use need effect acut treatment
migrain headach partial satisfi triptan typic
migrain attack respons oral triptan within two hour
symptom recur within hour mean
patient fail respond greater amount dissatisfi treatment
migrain patient also fail respond consist oral triptan
data effect hard-to-treat migrain group
post hoc analysi zotrip studi present
headach societi meet patient report wake present
headach pain moder sever intens difficult treat subset
patient receiv achiev co-primari endpoint pain
freedom hour vs control patient
achiev freedom bothersom symptom hour versu
placebo exhibit left percentag point benefit pain freedom
percentag point benefit freedom bothersom symptom
signific nomin roughli in-lin observ
overal popul
exhibit activ materi hard-to-treat migrain left delay treatment
schmidt et al experi delay treatment migrain use intracutan zolmitriptan intern headach societi
data effect hard-to-treat delay treatment
group hoc analysi zotrip studi also assess treatment
outcom patient receiv treatment less hour symptom
onset dose hour onset overal mean time
treatment hour median time hour delay
treatment subset hour onset achiev pain freedom
patient vs control net benefit nomin
achiev freedom mb hour vs placebo
gain nomin robust respons delay
treatment subset import underscor robust activ
across patient group even difficult headach
data opportun nausea symptom popul perform
patient state nausea symptom
necessarili bothersom symptom slightli better
overal pain freedom rate vs placebo mb
freedom vs addit post hoc analysi show among
patient receiv achiev freedom pain
bothersom symptom hour vs placebo differ
nomin rate meet co-primari endpoint
highest patient nausea solid efficaci patient
nausea well materi reduc rate symptom zotrip may
portend materi uptak patient view oral drug
difficult swallow retain patient kellerman et al pain
manag perform may challeng due
gastric dysfunct gastroparesi result headach
exhibit efficaci patient nausea zotrip trial
non-or acut migrain market current million opportun
us grow us current triptan market
billion current injectable/non-or migrain market
million us grow annual past five year
accord data gener symphoni health solut compil
btig certain sumatriptan autoinjector formul achiev revenu
million recent growth excess per year despit gener
competit oral triptan price remain robust novel formul
nasal version run inject due unmet
need effect therapeut acut migrain believ replac
mani novel form triptan compel efficaci
even difficult treat migraineur believ expand consider
non-or option triptan class
exhibit npv zosano acut treatment migrain
w/migrain migrain market specificsdiagnos w/migrain adult diagnos w/migrain adult diag treat adult diag adult diag acut treat adult diag tript treat estim penetr adult tx w/ estimate penetr estimate penetr acut tx dot treated- total doses- price/dos net price us revenue- total revenue- us revenu zosano revenu partner cogs- cog payment- royalti alza sg us profit loss eu/row licens partner upfront- mileston zsan royalti royalty- total mileston royalty- sublicens fee alza mileston royalty- total profit tax eff total total valu value-per-share
exhibit morn migrain common reason delay treatment
result difficult treat migrain
revenu econom npv zosano assum follow
revenu npv estim initi net price
estim approxim per treatment begin
launch expect compani rais price steadili annual
believ therapeut market rel effici mean
sg expens expect level occur multipl
brand triptan fight share believ consider
materi option migraineur difficult-to-treat migrain
morn migrain repres nearli half migrain exhibit
nausea materi compon shown exhibit
modest penetr diagnos migrain popul treat
triptan estim achiev revenu exceed million us
addit consider intern revenu collect us patent
life potenti extens ad protect
royalti paid alza licens adam technolog
solid pivot efficaci data zotrip hand assum discount
per annum long term shown exhibit result npv
share
fda consider acut migrain drug develop
base initi draft guidanc fda issu octob
final februari modest evolut clinic
requir develop medicin treatment acut
migrain regard trial design evid need investig
drug abl treat migrain moder sever intens also
necessari collect suffici baselin inform headach
headach intens presenc absenc associ symptom unilater
bilater headach aggrav exercis throb non-
throb abl verifi headach treat acut migrain
migrain efficaci endpoint measur migrain complex disord
multipl efficaci measur need consid therapeut acut
treatment addit headach migrain associ sever
symptom nausea photophobia sensit light phonophobia
sensit sound therefor measur drug effect focus headach
pain alon consid suffici grant regulatori claim fda
acut treatment migrain gener migrain pain symptom
measur util patient self-report questionnair
current statu migrain headach pain four-point likert scale
util associ
symptom binari scale present absent use
approv drug acut migrain therapeut past decad
involv demonstr effect four co-primari endpoint
pain nausea photophobia phonophobia recent consider
given headach pain nausea co-primari endpoint effici
altern approach util zosano industri
player consist patient prospect
identifi
bothersom migraine-associ symptom addit headach pain
specif zosano pivot co-primari endpoint zotrip
new standard proport patient report pain freedom hour
post-dos proport patient report freedom bothersom
symptom nausea photophobia phonophobia also hour
demonstr convinc efficaci measur examin
perform zotrip comparison hand emerg
acut migrain therapeut util revis fda acut migrain
endpoint efficaci look quit good exhibit
competit approach acut treatment migrain
efficaci
program
util
fda
therapystudyactiveplacebothera gainactiveplacebothera gainpain freedom freedom zembrac
addit develop
receptor agonist acut migrain
receptor emerg migrain recogn
receptor express trigemin ganglion secondari
trigemin neuron brainstem exhibit hypothesi emerg
stimul receptor select agonist potenti
inhibit central peripher neuron activ also releas cgrp
import neuropeptid therebi reduc acut migrain also
note receptor found endotheli smooth muscl cell
cerebr vessel lead conclus receptor involv
regul human brain vascular tone therefor thought
select agonist may potenti reduc migrain symptom
pain minim effect vasculatur
lasmiditan uniqu scaffold complet differ
triptan triptan act peripher constrict blood vessel
design penetr lasmiditan first class neural act
anti-migrain agent design cross blood/brain barrier
lasmiditan demonstr littl affin receptor
low potenc lasmiditan vasoconstrict receptor
appear quit import reduc vasoconstrict activ clinic data
confirm cardiac safeti lasmiditan result qtc
prolong oral dose mg healthi individu
compar trial moxifloxacin col studi lasmiditan also
appear result arrhythmia pro-arrhythm effect
lasmiditan develop colucid acquir rate
million cash base posit data first samauri two
phase trial addit posit data phase spartan trial
hand lilli file lasmiditan nda novemb
exhibit agon potenti migrain
earli adopt like focu cardiovascular contraind unmet
need base publish studi estim
million million migrain patient us cardiovascular
risk factor reinforc figur imshealth also project
triptan-tr patient carri cv risk contraind triptan use
level cv risk lasmiditan samurai studi
formal triptan contraind approxim million
migraineur expect major lilli promot
market effort least initi target larg competit
standpoint wide-open unmet need highli potent novel triptan
deliveri system see larg overlap market segment
note lasmiditan therapeut benefit pain freedom
samurai compar favor treatment benefit cgrp
half benefit seen measur
robustly-perform
evalu safeti efficaci lasmiditan dose
comparison placebo two hour dose freedom migrain
headach pain primari endpoint freedom
bothersom associ symptom migrain nausea phonophobia
photophobia key secondari endpoint samurai enrol patient
migrain cardiovascular risk factor cardiovascular diseas
samurai trial lasmiditan pain freedom rate
versu placebo therapeut benefit dose
exhibit molecul also reduc bothersom addit
associ symptom migrain hour compar placebo
delta dose exhibit right graph data
support posit phase spartan trial lasmiditan
achiev hour pain freedom vs placebo effect
freedom bothersom symptom hour
advers event effect cv liabil lasmiditan
appear dose-depend phase studi phase exhibit
right symptom frequent dizzi
materi occur patient exhibit left
notabl improv compar phase
respect may part due collect
methodolog employ samurai paresthesia skin tingl
somnol nausea fatigu vertigo also seen studi activ
receptor cerebellum later vestibular nucleu
lasmiditan probabl due meaning permeabl
molecul may contribut effect mild
moder intens studi
cgrp antagonist acut migrain
cgrp approach background migrain headach recogn
associ dilat cranial blood vessel dilat
thought result activ trigemin system nerv system
pertain face eye nose mouth jaw exhibit calcitonin gene-
relat peptid cgrp known vasodil found trigemin system
cgrp fact potent pepdiderg vasodil peripher
cerebr blood vessel cgrp receptor found mani area
highest densiti appear cerebellum dorsal spinal cord
receptor also present vasculatur heart blood vessel
much atria ventricl headach phase
migrain cgrp level increas thought increas cgrp
level primari caus vasodil associ migrain cgrp
inhibit therefor pharmacolog strategi pursu number
year treatment migrain
includ small molecul antagonist develop acut
treatment migrain molecul demonstr triptan-lik
efficaci appear devoid broad vasoconstrictor activ
unfortun number small molecul cgrp antagonist
discontinu varieti reason disclos
olcegep first cgrp antagonist though drug progress
beyond phase trial could administ intraven merck
phase trial
demonstr compar efficaci high dose zolmitriptan howev
six-month phase studi concern rais liver toxic
molecul associ elev hepat transaminas merck
second cgrp-receptor antagonist progress clinic trial
also discontinu due increas liver enzym concentr despit
better oral bioavail potenc telcagep
ho et al acut anti-migrain efficaci toler novel oral cgrp receptor antagonist
telcagep present american headach societi meet
molecul proceed acut migrain includ allergan
rate ubrogep biohaven rate rimegep
present posit data phase program earli
importantli cgrp data result remark consist across
studi potenti suggest rel similar efficaci cgrp
antagonist broadli view middl result solidifi
posit agent differenti efficaci treatment
differ observ zotrip better
zotrip cgrp program exhibit compani plan file
respect nda
plagu earli gener cgrp ubrogep rimegep may
overcom limit among patient treat rimegep
phase alt/ast uln placebo
patient rimegep placebo cohort elev
uln ubrogep achiev ii trial patient alt/ast
uln within day vs placebo patient elev
within day dose compar placebo patient treat
ubrogep achiev trial ast/alt uln within day vs
placebo case hy law occur either drug
addit consider cgrp use acut set addit
limit forese base convers migrain kol
believ may retic prescrib small molecul cgrp
antagonist acut migrain treatment patient alreadi take
long-act cgrp antibodi prevent limit small molecul cgrp
potenti modestli believ molecul non-cgrp mechan
may prefer combin patient present
full data cgrp program could elucid potenti
posit market approv
prevent treatment chronic migrain chronic migrain defin
migrain patient migrain attack day per month
least three month million suffer condit us
sever therapeut current approv reduc frequenc
migrain episod mani first approv use botox
first product approv fda prevent prophylaxi
chronic migrain patient qualifi chronic
migrain still signific disabl sever product
approv fda includ beta blocker propranolol inder
timolol blocadren anticonvuls topiram topamax valproic
acid depakot sever long-act cgrp molecul also emerg
cgrp antibodi emerg chronic migrain sever compani
success complet phase studi cgrp monoclon antibodi
includ rate aimovig erenumab teva
teva neutral analyst tim chiang fremanezumab
rate galcanezumab
alder
biopharmaceut aldr rate eptinezumab
long act approach larg design reduc number
occurr patient chronic migrain migrain per month
note antibodi like elimin migrain occurr
complet rather reduc number hyper-sensit migrain patient
exampl phase data episod migrain recent approv
aimovig list price show patient mean baselin
migrain day per month random monthli
subcutan inject observ statist signific reduct
monthli migrain day compar day observ placebo group
studi mean patient still like
requir acut use therapeut treat remain episod
addit prior kol discuss center around potenti
cardiovascular chronic suppress potent vasodil cgrp
long-liv molecul potenti limit util
zembrac system launch april follow januari
approv single-us autoinjector pen subcutan deliveri
sumatriptan treatment acut migrain devic
deliv drug use needl use requir inject site prep alcohol
pad dispos sharp contain potenti gauze/bandag
inject site afterward devic efficaci outlin exhibit
view quit strong observ also
maintain challeng needle-bas product
sumavel dosepro endo sumavel dosepro
approv needle-fre deliveri system sumatriptan
subcutan burst air endo rate
discontinu dose februari discontinu
neither decis driven product qualiti safeti
 zecuiti teva pharmaceut zecuiti iontophoret
transderm deliveri system sumatriptan launch septemb
acut treatment migrain drug deliveri done single-
use battery-pow patch wrap around patient upper arm
thigh market case patient report local burn
scar skin reaction case unresolv month
result june fda issu suspens market decre
includ pharmaci level recal teva discontinu
regulatori fda health agenc oversight compani whose
main busi drug develop zosano subject rigor
strenuou regulatori requir us fda intern
medicin develop regulatori agenc new drug approv
market promot approv drug product also regul fda
relat agenc throughout globe though zosano specif focu
ethic prescript pharmaceut place signific risk oper
believ risk time greater less
zosano depend upon progress migrain
zosano advanc molecul mani therapeut develop
expect take materi addit time resourc complet clinic
develop abl finish develop addit
zosano may seek collabor futur develop program
materi risk compani may abl enter collabor
therapi abl enter one term benefici
zosano zsan sharehold note valuat comment
develop program materi investor interest believ
repres materi portion zosano valuat therefor
progress progress effici materi risk zsan
share could trade neg result capit loss zsan sharehold
competit risk price acut migrain therapeut
expect introduc consid patient us suffer
migrain headach highli generic market believ
differenti uniqu deliveri howev profil
emerg anticipatedwith rapid activ conveni well-toler
microproject patch dosingth competit environ may
extrem challeng despit success enough efficaci safeti
pivot studi ensur licensur addit guarante level
efficaci demonstr zotrip support adopt payor
patient physician competit agonist cgrp antagonist
cgrp-focus monoclon antibodi could also emerg potenti
harm adopt current competit cgrp
approach though expect appeal certain set
pressur greater expect materi risk zsan
novel regulatori endpoint acut migrain zosano util novel
endpoint pursuit approv therapeut acut migrain
standard guidanc place develop migrain
therapeut sever decad octob fda issu new draft
guidanc approv acut migrain final februari
guidanc repres advanc think regul space
contain novel endpoint pivot studi endpoint includ
primari endpoint pain focu addit symptom
individu bothersom addit migrain symptom
though potenti benefici design novel phase endpoint trial
structur also repres increment risk zosano
pathway zosano util abbrevi registr
pathway pursuit approv migrain reli
extent inform drug zolmitriptan though mani molecul
use pathway approv previous guarante
suitabl type approach zosano fda ultim
decid approach appropri materi addit
resourc may need expend gain approv result signific
chang time product introduct would like significantli
manufactur risk fda recent extrem vigil inspect
drug manufactur plant homolog could subject addit risk
type fda regard manufactur therapeut
develop submit licensur us jurisdict
throughout globe approv meaning problem
zosano manufactur oper contract
accomplish goal could materi zsan share
adam drug deliveri technolog risk drug deliveri devic subject
robust fda requir regulatori approv like drug product
agenc close regul post-approv market safeti efficaci
drug deliveri devic adam devic util failur
adam technolog achiev rigor standard fda requir
approv migrain achiev potenti adam
program could materi detriment program zsan
share result failur adam program continu meet post-
neg impact potenti util adam technolog broadli
ultim also zsan share
potenti risk though list mean all-inclus
addit risk zosano zsan share zosano incur
signific loss sinc incept expect incur loss least next
sever quarter may never sustain profit risk addit
financ compani materi may result materi dilut
exist zsan sharehold zosano also singl lead product candid
limit oper histori despit manag team develop
histori histori commerci pharmaceut product
may make difficult evalu establish prospect futur
viabil zosano emerg growth compani reduc
disclosur requir emerg growth compani may make
